Blood flow regulates transcription via ligand-dependent Alk1 activity

Anthony R. Anzell,Amy Biery Kunz,James P. Donovan,Thanhlong G. Tran,Xinyan Lu,Sarah Young,Beth L. Roman

DOI: https://doi.org/10.1101/2024.01.25.576046

2024-01-25

Abstract:Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by the development of arteriovenous malformations (AVMs) that can result in significant morbidity and mortality. HHT is caused primarily by mutations in bone morphogenetic protein receptors /ALK1, a signaling receptor, or endoglin ( ), an accessory receptor. Because overexpression of prevents AVM development in both and null mice, enhancing expression may be a promising approach to development of targeted therapies for HHT. Therefore, we sought to understand the molecular mechanism of regulation. We previously demonstrated in zebrafish embryos that is predominantly expressed in arterial endothelial cells and that expression requires blood flow. Here, we document that flow dependence exhibits regional heterogeneity and that expression is rapidly restored after reinitiation of flow. Furthermore, we find that expression is significantly decreased in mutants that lack the circulating Alk1 ligand, Bmp10, and that BMP10 microinjection into the vasculature in the absence of flow enhances expression in an Alk1-dependent manner. Using a transgenic reporter line, we find that flow and Bmp10 regulate at the level of transcription. Finally, we observe similar ALK1 ligand-dependent increases in in human endothelial cells subjected to shear stress. These data suggest that Bmp10 acts downstream of blood flow to maintain or enhance expression via a positive feedback mechanism, and that ALK1 activating therapeutics may have dual functionality by increasing both ALK1 signaling flux and expression.

Developmental Biology